Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

2.970 -0.090 (-2.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 384,124
Open 3.040
Bid (Size) 2.920 (3)
Ask (Size) 2.990 (4)
Prev. Close 3.060
Today's Range 2.910 - 3.040
52wk Range 2.120 - 5.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
From Mind Medicine Inc
Via Business Wire
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
Via Benzinga

Performance

YTD
+19.28%
+19.28%
1 Month
-25.19%
-25.19%
3 Month
-18.18%
-18.18%
6 Month
-2.62%
-2.62%
1 Year
-10.27%
-10.27%

More News

Read More
September Summary: Largest Psychedelic Drug Stocks Dropped 14%
Via Talk Markets
Analyst Expectations for Mind Medicine's Future
Via Benzinga
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price
Via Talk Markets
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
Via FinancialNewsMedia
Topics Economy
Exposures Economy Product Safety
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Via Benzinga
Exposures Product Safety
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
Via Benzinga
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week
Via Talk Markets
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
From MindMed
Via Business Wire
Combining MDMA With Psilocybin Or LSD Could Reduce Difficult Trips, New Study Shows
Via Benzinga
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
Via Benzinga
MindMed's Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone
Via Benzinga
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
6 Largest Psychedelic Compound-Based R & D Stocks In Decline
Via Talk Markets
The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week
Via Talk Markets
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Via Benzinga
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
Via Talk Markets
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Via Benzinga
MindMed to Participate at September Investor Conferences
From Mind Medicine (MindMed) Inc.
Via Business Wire
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.